Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

Completed · Phase 1

Conditions studied: Healthy

In brief

This will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male subjects to evaluate the Absorption, Metabolism, and Excretion of Poziotinib following a single oral dose of \[14C\]-poziotinib to healthy male subjects.

Key facts

Study ID

NCT04436562

Run by

Spectrum Pharmaceuticals, Inc

People needed

8

Starts

2020-05-29

Expected to finish

2020-07-17

Last updated by the study team

2021-01-15

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: accepted.

Where it is running

• Covance Clinical Research Unit, Inc. — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.